Grant: Alliance Grants
McGill University
$50,000.00
Loading and release of RNA for COVID-19 vaccines: direct visualization of lipid nanoparticle delivery vehicles._x000d_ _x000d_ _x000d_ _x000d_
FY 2020-21
Summary
The coronavirus pandemic has created an immediate need for Covid-19 vaccines and therapies. Several companies have developed vaccines which are already in clinical trials, where lipid nanoparticles (LNPs) are used to deliver RNA to target cells in humans. Here they stimulate the production of a single viral protein which elicits an immune response. RNA-based vaccines are potentially safer, cheaper, and lower dose than other vaccines, and can be manufactured fast enough to respond to the kind of global pandemic in which we find ourselves today. This is a completely new vaccine technology and there is much to learn and optimize about its mode of action. Our proposal aims to visualize the interactions of RNA with LNP delivery vehicles, characterizing the structure and RNA-carrying capacity of LNPs, in order to better understand and control the delivery of these therapeutic compounds to targeted cells in the body.
Precision Nanosystems Inc (PNI) has developed the LNP delivery platform technology used by pharmaceutical companies in their development of vaccines and other Covid-19 therapeutics. The Leslie Lab at McGill University has developed a novel single-particle imaging technique called Convex Lens-induced Confinement ("CLiC"), which enables direct imaging of individual nanoparticles and molecules as they interact in solution. Our collaboration combines two made-in-Canada technologies to accelerate the development of Covid-19 vaccines. Using CLiC microscopy to study PNI's nanoparticle delivery technology, we can make new discoveries about the structure of LNPs, how they interact with RNA cargo, and how they deliver RNA to cells. CLiC can yield more detailed information than current techniques can provide, so we will gain insights into LNP behavior that were previously unattainable. Our research will create new tools and allow vaccine developers to design and optimize RNA-based therapeutics more efficiently, bringing much needed therapies more quickly to market.
Program
Alliance Grants
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
554165-2020
Name nom
Leslie, Sabrina
Department département
Physics
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Loading and release of RNA for COVID-19 vaccines: direct visualization of lipid nanoparticle delivery vehicles._x000d_
_x000d_
_x000d_
_x000d_
Keyword
NSERC
Application summary
The coronavirus pandemic has created an immediate need for Covid-19 vaccines and therapies. Several companies have developed vaccines which are already in clinical trials, where lipid nanoparticles (LNPs) are used to deliver RNA to target cells in humans. Here they stimulate the production of a single viral protein which elicits an immune response. RNA-based vaccines are potentially safer, cheaper, and lower dose than other vaccines, and can be manufactured fast enough to respond to the kind of global pandemic in which we find ourselves today. This is a completely new vaccine technology and there is much to learn and optimize about its mode of action. Our proposal aims to visualize the interactions of RNA with LNP delivery vehicles, characterizing the structure and RNA-carrying capacity of LNPs, in order to better understand and control the delivery of these therapeutic compounds to targeted cells in the body.
Precision Nanosystems Inc (PNI) has developed the LNP delivery platform technology used by pharmaceutical companies in their development of vaccines and other Covid-19 therapeutics. The Leslie Lab at McGill University has developed a novel single-particle imaging technique called Convex Lens-induced Confinement ("CLiC"), which enables direct imaging of individual nanoparticles and molecules as they interact in solution. Our collaboration combines two made-in-Canada technologies to accelerate the development of Covid-19 vaccines. Using CLiC microscopy to study PNI's nanoparticle delivery technology, we can make new discoveries about the structure of LNPs, how they interact with RNA cargo, and how they deliver RNA to cells. CLiC can yield more detailed information than current techniques can provide, so we will gain insights into LNP behavior that were previously unattainable. Our research will create new tools and allow vaccine developers to design and optimize RNA-based therapeutics more efficiently, bringing much needed therapies more quickly to market.